Definition/Introduction
Understanding the concept of drug clearance is essential when determining the dosing of medications. When a medication is administered intravenously, the drug ends up either in the blood plasma or redistributes into the extravascular volume. The drug present in the plasma can be removed from the body primarily through the kidneys and liver. Drug clearance is defined as the volume of plasma cleared of a drug over a specified time period.[1] Thus, the unit of measurement for drug clearance is volume/time. Another equation can calculate clearance. Clearance is equal to the rate at which a drug is removed from plasma(mg/min) divided by the concentration of that drug in the plasma (mg/mL). The total ability of the body to clear a drug from the plasma is renal clearance plus hepatic clearance plus clearance from all other tissues. It is important to be aware of the fact that clearance does not tell us the amount of drug cleared. For example, let’s say drug X has a renal clearance of 20 mL/min and hepatic clearance of 5 mL/min. The total clearance of drug X would be 25 mL of plasma is cleared of drug X per minute.
Issues of Concern
Elimination kinetics play an essential role in drug clearance. In first-order kinetics, a constant fraction of the drug is cleared per unit time because the mechanisms used for elimination are not saturated. Thus, drug clearance does not vary with changes in the plasma concentration of a drug when drug elimination occurs by first-order kinetics. The vast majority of drug elimination takes place by first-order kinetics. In zero-order kinetics, the same quantity of drug is eliminated per unit time because the mechanisms used for elimination are saturated. In zero-order kinetics, drug clearance can vary due to changes in the plasma concentration of a drug.[2]
As stated in the previous examples, drug clearance plays an important role in determining drug concentration and thus dosing regimens. Steady-state plasma concentration is inversely related to the total body clearance of a drug. The dosing rate is calculated by multiplying total body clearance by a drug’s desired steady-state concentration, assuming the drug is fully bioavailable. For patients with cardiac insufficiency, kidney and liver disease, drug clearance can be severely affected. The ability of serum proteins to bind to drugs also can play a role in clearance. A decrease in serum proteins may cause an increase in free drug concentration in the plasma, thus increasing its rate of elimination from the body.[3][4]
Clinical Significance
For patients with renal or hepatic disease, care is necessary to adjust dosages. In patients with severe liver disease, maintenance dosages should be reduced based on the percent of hepatic clearance of the drug.[5][6] Dosing in kidney disease tends to be complicated. Many drug companies provide dosage guidelines for each stage of renal disease. Dose reductions are often necessary for patients with renal disease.[7] The interaction of drugs with the kidney, type of kidney disease, and creatinine clearance need factor into dosing and therapy. Another factor that merits consideration is age because drug clearance decreases as patients get older.[8][9]
Nursing, Allied Health, and Interprofessional Team Interventions
The healthcare team, e.g., physicians, nurses, pharmacists, etc., needs to work together to ensure the safe and effective pharmacotherapy of their patients. Understanding the concept of drug clearance is essential when determining the dosing of medications. For patients with renal, hepatic, or cardiac disease, care is often necessary to adjust drug dosages to prevent adverse drug effects. [Level 5]
References
- 1.
Toutain PL, Bousquet-Mélou A. Plasma clearance.
J Vet Pharmacol Ther. 2004 Dec;27(6):415-25. [
PubMed: 15601437]
- 2.
Wadhwa RR, Cascella M.
StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Mar 6, 2023. Steady State Concentration. [
PMC free article: PMC553132] [
PubMed: 31985925]
- 3.
Jokanovic N, Tan EC, Sudhakaran S, Kirkpatrick CM, Dooley MJ, Ryan-Atwood TE, Bell JS. Pharmacist-led medication review in community settings: An overview of systematic reviews.
Res Social Adm Pharm. 2017 Jul-Aug;13(4):661-685. [
PubMed: 27665364]
- 4.
Levy G. Pharmacokinetics in renal disease.
Am J Med. 1977 Apr;62(4):461-5. [
PubMed: 851113]
- 5.
Delcò F, Tchambaz L, Schlienger R, Drewe J, Krähenbühl S. Dose adjustment in patients with liver disease.
Drug Saf. 2005;28(6):529-45. [
PubMed: 15924505]
- 6.
Morgan DJ, Smallwood RA. Clinical significance of pharmacokinetic models of hepatic elimination.
Clin Pharmacokinet. 1990 Jan;18(1):61-76. [
PubMed: 2178850]
- 7.
Lea-Henry TN, Carland JE, Stocker SL, Sevastos J, Roberts DM. Clinical Pharmacokinetics in Kidney Disease: Fundamental Principles.
Clin J Am Soc Nephrol. 2018 Jul 06;13(7):1085-1095. [
PMC free article: PMC6032582] [
PubMed: 29934432]
- 8.
Toto RD. Conventional measurement of renal function utilizing serum creatinine, creatinine clearance, inulin and para-aminohippuric acid clearance.
Curr Opin Nephrol Hypertens. 1995 Nov;4(6):505-9; discussion 503-4. [
PubMed: 8591059]
- 9.
Butler JM, Begg EJ. Free drug metabolic clearance in elderly people.
Clin Pharmacokinet. 2008;47(5):297-321. [
PubMed: 18399712]
Disclosure: Gaither Horde declares no relevant financial relationships with ineligible companies.
Disclosure: Vikas Gupta declares no relevant financial relationships with ineligible companies.
